Junshi Biosciences Announces Full Year 2021 Financial Results and Provides Corporate Updates

-Tackling the COVID-19 pandemic challenge with multi-pronged strategies - Pipeline progressed and expanded substantially SHANGHAI, China, March 31, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi

Related Keywords

Taiwan ,Shanghai ,China ,United States ,Hong Kong ,Uzbekistan ,Lingang ,Jiangxi ,Hong Kong Special Administrative Region ,Hong Kong General ,Russia ,Macao ,Macau General ,Macau ,Chinese ,Juntop Biosciences ,Junshi Bioscience ,Cong Li ,Junshi Biosciences ,Zhi Li ,Shanghai Junshi Biotechnology Co Ltd ,Company The Shareholders ,Lingang Production ,Institute Of Microbiology ,Coherus Biosciences Inc ,Wigen Biomedicine Technology Shanghai Co Ltd ,Shanghai The Lingang Production ,Suzhou Vigonvita Biomedical Co Ltd ,Astrazeneca ,China Securities Regulatory Commission ,National Medical Products Administration Of China ,Astrazeneca Pharmaceutical Co Ltd ,Pr Team ,Immorna Hangzhou Biotechnology Co Ltd ,Topalliance Biosciences Inc ,Risen Suzhou Biosciences Co Ltd ,Shanghai Juntop Biosciences Co Ltd ,Company Lilly ,Eirene Biotech Co Ltd ,Ir Team ,Drug Administration ,Data Monitoring Committee ,Shanghai Stock Exchange ,Chinese Academy Of Sciences ,Shanghai Public Health Clinical Center ,National Drug List For Basic Medical Insurance ,Board Of Directors The Company ,Shanghai Junshi Biosciences Co Ltd ,Coherus Biosciences ,Main Board ,Stock Exchange ,Hong Kong Limited ,Kong Stock ,Fast Track Designation ,United States Food ,Investigational New Drug ,Breakthrough Therapy Designation ,National Medical Products Administration ,Exclusive License ,Commercialization Agreement ,Coherus Territory ,Wigen Biomedicine Technology ,Topalliance Biosciences ,Biologics License Application ,Prescription Drug User Fee Act ,Independent Data Monitoring Committee ,Progression Free Survival ,Overall Survival ,Commercialization Agreement Junshi Biosciences ,Wigen Biomedicine ,Chinese Academy ,Macao Special Administrative Region ,Emergency Use Authorization ,Central Asian ,North Africa ,National Drug List ,Basic Medical Insurance ,Work Related Injury Insurance ,Maternity Insurance ,Astrazeneca Pharmaceutical ,Lingang Production Base ,China Securities Regulatory ,Emergency Use Authorizations ,Junshi ,Iosciences ,Nnounces ,Bull ,Ear ,021 ,Financial ,Results ,Rovides ,Corporate ,Updates ,